Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics

Volumn 27, Issue 10, 2005, Pages 1535-1547

  Roberts, Victor Lawrence ^a   Stewart, John ^b   Issa, Maher ^b   Lake, Barbara ^a   Melis, Robert ^b  

^a Sanofi aventis ^*

^b SANOFI   (France)

Author keywords

Biguanide; Diabetes; HbA1c; Sulfonylurea; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TITRIMETRY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 28444482714     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.10.017     Document Type: Article

References (38)

1. Abrahamson M.J. Optimal glycemic control in type 2 diabetes mellitus: Fasting and postprandial glucose in context Arch Intern Med 164 2004 486 491
2. [published correction appears in Lancet. 1999;354:602] UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33) Lancet 352 1998 837 853
3. Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multipletherapies (UKPDS 49) JAMA 281 1999 2005 2012
4. Mudaliar S., and Henry R.R. Combination therapy for type 2 diabetes Endocr Pract 5 1999 208 219
5. Bayraktar M., Van Thiel D.H., and Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients Diabetes Care 19 1996 252 254
6. Erle G., Lovise S., and Stocchiero C. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus highdose glyburide alone in the treatment of type 2 diabetic patients Acta Diabetol 36 1999 61 65
7. Tosi F., Muggeo M., and Brun E. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: A randomized, doubleblind,comparative study Metabolism 52 2003 862 867
8. Feinglos M.N., and Bethel M.A. Oral agent therapy in the treatment of type 2 diabetes Diabetes Care 22 Suppl 3 1999 C61 C64
9. Cohen F.J., Neslusan C.A., Conklin J.E., and Song X. Recent anti hyperglycemic prescribing trends for US privately insured patients with type 2 diabetes Diabetes Care 26 2003 1847 1851
10. Kabadi U.M. Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents Manag Care 13 2004 48 59
11. Nathan D.M. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus N Engl J Med 347 2002 1342 1349
12. Scheen A.J., and Lefebvre P.J. Troglitazone: Anti hyperglycemic activity and potential role in the treatment of type 2 diabetes Diabetes Care 22 1999 1568 1577
13. Kermani A., and Garg A. Thiazolidinedioneassociated congestive heart failure and pulmonary edema Mayo Clin Proc 78 2003 1088 1091
14. Tan G.H., and Nelson R.L. Pharmacologic treatment options for non-insulindependent diabetes mellitus Mayo Clin Proc 71 1996 763 768
15. Korytkowski M., Thomas A., and Reid L. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes Diabetes Care 25 2002 1607 1611
16. Charpentier G., Fleury F., and Kabir M. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients Diabet Med 18 2001 828 834
17. Davis S.N. The role of glimepiride in the effective management of type 2 diabetes J Diabetes Complications 18 2004 367 376
18. Rosenstock J., Samols E., Muchmore D.B., Schneider J. Glimepiride Study Group Glimepiride, a new once-daily sulfonylurea. A doubleblind placebo-controlled study of NIDDM patients Diabetes Care 19 1996 1194 1199
19. Goldberg R.B., Holvey S.M., Schneider J. Glimepiride Protocol #201 Study Group A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents Diabetes Care 19 1996 849 856
20. Schade D.S., Jovanovic L., and Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful J Clin Pharmacol 38 1998 636 641
21. Bell D.S., and Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus Endocr Pract 8 2002 271 275
22. Dailey G.E. III, Noor M.A., and Park J.S. Glycemic control with glyburide/ metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, doubleblind trial Am J Med 116 2004 223 229
23. Ovalle F., and Bell D.S. Triple oral antidiabetic therapy in type 2 diabetes mellitus Endocr Pract 4 1998 146 147
24. Rheney C.C., and Kirk J.K. Performance of three blood glucose meters Ann Pharmacother 34 2000 317 321
25. American Diabetes Association Evidence-based nutrition principles and recommendations for the treat ment and prevention of diabetes and related complications Diabetes Care 25 2002 550 560
26. Fitzgerald J.T., Davis W.K., and Connell C.M. Development and validation of the Diabetes Care Profile Eval Health Prof 19 1996 208 230
27. Ware J.J., Kosinski M., and Keller S. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity Med Care 34 1996 220 233
28. Feeny D., Furlong W., Boyle M., and Torrance G.W. Multi-attribute health status classification systems. Health Utilities Index Pharmacoeconomics 7 1995 490 502
29. Everitt B.S., and Pickles A. Statistical Aspects of the Design and Analysis of Clinical Trials 1999 Imperial College Press London
30. Orbay E., Sargin M., and Sargin H. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes Endocr J 51 2004 521 527
31. Nesto R.W., Bell D., and Bonow R.O. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 108 2003 2941 2948
32. Lebovitz H.E. Insulin secretagogues: Sulfonylureas and meglitinides Le Roith D. Taylor S.I. Olefsky J.M. Diabetes Mellitus: A Fundamental and Clinical Text 2000 Lippincott Williams & Wilkins Philadelphia 769 778
33. UK Prospective Diabetes Study Group UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes Diabetes Care 21 1998 87 92
34. Coniff R.F., Shapiro J.A., Seaton T.B., and Bray G.A. Multicenter, placebocontrolled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plusacarbose innon-insulin-dependent diabetes mellitus Am J Med 98 1995 443 451
35. Testa M.A., and Simonson D.C. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, doubleblind trial JAMA 280 1998 1490 1496
36. Van der Does F.E., De Neeling J.N., and Snoek F.J. Symptoms and wellbeing in relation to glycemic control in type II diabetes Diabetes Care 19 1996 204 210
37. Wikblad K., Leksell J., and Wibell L. Health-related quality of life in relation to metabolic control and late complications in patients with insulin dependent diabetes mellitus Qual Life Res 5 1996 123 130
38. Hanestad B.R., and Graue M. To maintain quality of life and satisfactory metabolic control in type II diabetes patients Qual Life Res 4 1995 436 437